Twice‑yearly injectable HIV regimen treatment demonstrates strong efficacy and safety in Phase 2 trial

A new study published in The Lancet Microbe reports that the first twice-yearly injectable HIV treatment regimen – the combination of lencapavir, teropavimab and zinlirivimab – achieved high rates of viral suppression and demonstrated a favorable safety profile at 26 weeks. Led by Joe Aron, MD, a researcher at the UNC Institute for Global Health…

Read More

Brain immune cells may help build Alzheimer's plaques

A new study led by researchers at VIB and KU Leuven shows that immune cells called microglia can actively promote plaque formation in Alzheimer’s disease, challenging the long-held view that these cells serve only as protectors against plaque buildup. The findings were recently published in the Proceedings of the National Academy of Sciences. Source link

Read More